Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.78 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.78 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.78 |
| ▸ | NNMT | P40261 | 3/20 | 0.78 |
| ▸ | NSD2 | O96028 | 2/20 | 0.78 |
| ▸ | PCMT1 | P22061 | 2/20 | 0.78 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.78 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.78 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.78 |
| ▸ | RNMT | O43148 | 1/20 | 0.78 |
| ▸ | INMT | O95050 | 1/20 | 0.78 |
| ▸ | TPMT | P51580 | 1/20 | 0.78 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.78 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.78 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.78 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.78 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.78 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.78 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sinefungin SCHEMBL38665462 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL3400839 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL10400321 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL24478706 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL167609 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL23607779 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL19421010 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL14174630 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL20992057 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 | |
| Sinefungin SCHEMBL30779328 | 0.88 | NSD2 (1.00) | EHMT2EHMT1DOT1LNNMTNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| EP-1373185-B1 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | AMINEX THERAPEUTICS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1373185-A4 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6963010-B2 | Anticancer agents; osteoporosis; autoimmune disease | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1373185-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | Mediquest Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2002053519-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | EHMT2 176/4885EHMT1 249/4885DOT1L 595/4885 |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | EHMT2 387/4885EHMT1 248/4885DOT1L 2184/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | EHMT2 387/4885EHMT1 248/4885DOT1L 2184/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | EHMT2 176/4885EHMT1 249/4885DOT1L 595/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | EHMT2 2679/4885EHMT1 2131/4885DOT1L 4266/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | EHMT2 2679/4885EHMT1 2131/4885DOT1L 4266/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | EHMT2 1803/4885EHMT1 1288/4885DOT1L 862/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | EHMT2 1787/4885EHMT1 1757/4885DOT1L 4058/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | EHMT2 1787/4885EHMT1 1757/4885DOT1L 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.